Harbour BioMed Announces 2023 Interim Results



CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2023 /PRNewswire/ — Harbour BioMed (“HBM”, or the “Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on…

Leave a Reply